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Introduction
Novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been 
described to induce a variety of clinical conditions [1]. While some patients have flu-like 
symptoms only, others develop serious coronavirus disease 2019 (COVID-19), which has 
been associated with high inflammatory burden including vascular inflammation, myocarditis 
and cardiac arrhythmias that can result in cardiogenic shock (CS) [1]. CS in general is still a 
challenging disease [2], but in the context of COVID-19 associated CS, mortality is especially
high and treatment recommendations or promising strategies are lacking.
Compassionate use of convalescence plasma is essayed in multiple centers today, but 
convalescence plasma alone does not comprise immediate CS stabilization. It has capabilities 
to prevent severe COVID-19 outbreak [3], but in COVID-19 associated CS many physicians 
are left blanked-faced because of widely lacking evidence.
Utilization of catecholamines in CS is accompanied by side effects and the use of 
mechanical circulatory support in CS is associated with risk of infection, bleeding, vessel or 
nerve injury [4]. Therefore, substitute and new therapeutic options are warranted, especially to
manage hypoperfusion and concomitant organ failure [5]. Calcium sensitizer levosimendan 
was developed to enhance inotropy [2], but levosimendan is under debate because available 
trials do not reflect the initial drug’s promises [5], while no trial has tested the impact of 
levosimendan in COVID-19 associated CS to date.
In this context, reported herein, is a first case on a breakthrough of COVID-19 induced
CS using synergistic effects of levosimendan in addition to convalescence plasma therapy in 
an 84-year-old.
Case presentation
An 84-year-old female with cardiovascular disease, including transcatheter aortic 
valve replacement in 2019, permanent atrial fibrillation, heart failure and chronic renal failure 
was admitted complaining of shortness of breath, blood pressure 85/60 mmHg, heart rate 
113/min. Rapidly, she developed high fever, non-productive cough and coronavirus 
polymerase chain reaction was positive for novel coronavirus SARS-CoV-2. The patient 
received 3 preparations of convalescent plasma (190–230 mL) on day 1, 3 and 5 after 
preexistent IgA and IgG antibodies had been excluded (anti-SARS-CoV-2-ELISA, 
EUROIMMUN AG, Lübeck, Germany).
Only hours after hospital admittance her hemodynamics rapidly deteriorated and she 
developed CS with severely impaired left ventricular function (LVEF 30%). Coronary 
angiography excluded coronary artery disease, developing COVID-19 associated CS.
Her clinical condition progressively deteriorated despite optimal guideline-derived CS 
medical treatment [2], with dyspnea at rest, tachypnea, orthopnea and cyanosis, requiring 
rising doses of intravenous inotrope drugs (dobutamine 8 μg/kg/min, norepinephrine 0.5 
μg/kg/min). She developed systemic hypoperfusion syndrome resulting in multiple organ 
failure, high serum lactate levels and central venous oxygen saturation of 30% (Table 1).
At this time, available CS treatment options were exhausted and for further 
aggravation of COVID-19 induced CS, levosimendan was applied as a bailout compassionate 
therapy. After that, improvement in hemodynamics and clinical parameter eventuated (Table 
1). Lactic acidosis came to regression and multiorgan failure slowly reversed. Given the life-
threatening COVID-19 associated CS condition in this patient, add-on treatment with 
intravenous levosimendan 2.5 mg (12 μg/kg as bolus over 10 min and 0.1 μg/kg/min as 
infusion) adjunctive to convalescence plasma therapy resulted in improvement and finally 
breakthrough of COVID-19 associated CS, including clinical improvements, such as relief 
from dyspnea and orthopnea.
Discussion
According to available research, herein, is the first clinical in-vivo observation 
reported using the combined application of convalescence plasma and novel calcium 
sensitizer levosimendan to overcome acute CS in a COVID-19 patient. After five days of 
treatment the patient was stable enough to be discharged from intensive care unit and weeks 
after hospital admission she returned to her ordinary daily life.
We describe a novel treatment strategy for a complex clinicaly new disease pattern, 
with no verified therapy scheme known so far. During this life-threatening condition 
additional use of levosimendan resulted in potential synergistic effects resulting in 
hemodynamic stabilization and our strategy overcame CS not requiring invasive mechanical 
circulatory support (MCS), as MCS invasiveness in an 84-year-old carries notable risks such 
as bleeding, infection or thromboembolic complications [4, 6].
Moreover, levosimendan is currently the subject of intense discussion too, as this 
novel drug promises positive inotropic effects, but large clinical trials failed to confirm these 
effects [7]. European Society of Cardiology (ESC) guidelines recommend levosimendan in 
acute heart failure only to reverse effects of beta-blockade, if beta-blockade is considered to 
contribute to CS (evidence class IIb, level C) [2]. Furthermore, the drug may contribute to 
severe arrhythmia, myocardial ischemia and hypotension (evidence class I, level C). ESC 
guidelines recommend levosimendan only in combination with other established inotropes, 
such as dobutamine or vasopressors in CS [2] and levosimendan has undesired effects such as 
vasodilatation and arrhythmia. In addition to that current goal in COVID19 treatment is to 
reduce intravascular fluids to avoid mechanical ventilation while CS treatment often requires 
intravascular fluids. This relation seems incompatible and hemodynamic monitoring is 
challenging [8], why levosimendan use can only be understood as a bailout strategy.
Large randomized controlled trials such as the CHEETAH study investigated 
hemodynamic effects of levosimendan in 506 high-risk patients undergoing cardiac surgery, 
finding no benefit in terms of mortality or other clinical endpoints [5]. Similarly, the LEVO-
CTS trial [9] or the LeoPARDS trial [10] found no benefit in comparison to placebo.
Besides available evidence, there is no randomized controlled clinical trial, nor any 
clinical evidence on how to manage therapy-refractory COVID-19 CS because our first in-
vivo observation of synergistic effects for the combination of levosimendan and plasma 
therapy brings the hypothesis that levosimendan may be an option in critical COVID-19 
induced CS [5]. Synergistic effects may derive from the timely critical combination of the 
immune system response through convalescence plasma therapy, but which requires 
hemodynamic stability and sufficient circulation that may have been provided through 
levosimendan application. This engaged synergy appears to have facilitation of breakthrough 
of COVID-19 CS in our presented case.
However, additional research is needed to better define indications for, and benefits of,
levosimendan therapy. Nevertheless, studies of COVID-19 CS patients are difficult to 
conduct, but scientific data is important to provide assistance on how to best treat COVID-19 
CS patients and whether levosimendan application in combination with other therapeutics 
might lead to similar benefits as observed in our reported case.
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Table 1. Laboratory parameters in COVID-19 cardiogenic shock
Addition of levosimendan 
in this COVID-19 patient 
Laboratory 
parameters
Day 1 Night 1 Day 2 Night 2 Day 3
Troponin 147 192 159 76 89
BUN [mg/dL] 94 128 123 75 72
Creatinine [mg/dL] 1.4 1.9 1.7 1.7 1.1
MDRD [mL/min] 36 25 29 47 53
GOT [U/L] 21 1540 560 607 537
GPT [U/L] 8 649 275 438 400
GGT [U/L] 105 239 93 160 150
LDH [U/L] 246 1240 599 534 497
Bilirubin [mg/dL] 2.23 1.54 3.32 1.03 0.93
Interleukin 6 79 205 98 40 35
NT-proBNP [pg/mL] 12800 10800 10500 7290 2180
CRP [mg/dL] 8.4 11 10 8.9 6.0
Procalcitonin 
[ng/mL]
< 0.2 < 0.2 < 0.2 < 0.2 < 0.2
Blood gas analyses
pH 7.457 7.421 7.421 7.479 7.490
pCO2 [mmHg] 34.0 25.6 26.6 28.4 30.1
HCO3 [mmol/L] 24.4 17.2 19.5 23.0 24.7
Base excess –0.9 –7.2 –2.5 –1.7 –0.4
Lactate [mmol/L] 3.9 6.7 8.6 4.1 1.5
CVPO2 [mmHg] 34.6 26.1 43.2 46.8 53.8
BUN — blood urea nitrogen; CRP — C-reactive protein; CVPO2 — central venous oxygen 
saturation; GGT — gamma-glutamyl transpeptidase; GOT — glutamic-oxaloacetic 
transaminase; GPT — glutamic-pyruvic transaminase; HCO3 — bicarbonate; LDH — lactate 
dehydrogenase; MDRD — modification of diet in renal disease; NT-pro BNP — N-terminal 
pro-B-type natriuretic peptide; pCO2 — partial pressure of carbon dioxide; pH — pH, decimal
logarithm of the reciprocal of the hydrogen ion activity
